Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
79 hedge funds and large institutions have $315M invested in Generation Bio in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 30 increasing their positions, 26 reducing their positions, and 13 closing their positions.
28% more capital invested
Capital invested by funds: $247M → $315M (+$68.4M)
15% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.89% less ownership
Funds ownership: 9.62% → 8.72% (-0.89%)
5% less funds holding
Funds holding: 83 → 79 (-4)
15% less call options, than puts
Call options by funds: $29K | Put options by funds: $34K
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.01M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$599K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$457K |
| 4 |
BlackRock
New York
|
+$416K |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$414K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Atika Capital Management
New York
|
-$1.53M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.5M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$688K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$564K |
| 5 |
JFG
Jefferies Financial Group
New York
|
-$237K |
GBIO Hedge Fund Activity: Q2 2023 in Review
79 of the 6,371 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q2 2023, worth a combined $315M — up 28% from $247M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of GBIO and 9 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 30 added.
The largest buyer was JP Morgan Chase, adding an estimated $2.01M. The largest seller was Atika Capital Management, exiting entirely with an estimated $1.53M sold.
- 79 institutional investors held Generation Bio (GBIO) as of Q2 2023, down from 83 in Q1 2023.
- Funds reported $315M of Generation Bio stock for Q2 2023, up 28% quarter-over-quarter.
- 9 funds opened new Generation Bio positions in Q2 2023 and 13 closed out, a net change of -4 holders.
- The largest Generation Bio buyer in Q2 2023 was JP Morgan Chase, an estimated $2.01M added.
- The largest Generation Bio seller in Q2 2023 was Atika Capital Management, an estimated $1.53M sold.
Based on aggregated 13F filings for Q2 2023.